Ukko is a biotechnology company focused on developing immunotherapies for the treatment of allergies and other immune-mediated diseases.
Ukko has raised $45.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.
Ukko's investors include Khosla Ventures, PeakBridge, Innovation Endeavors, Israel Biotech Fund, Fall Line Capital.
Ukko is headquartered in Palo Alto, United States.
Ukko is a biotechnology company focused on developing immunotherapies for the treatment of allergies and other immune-mediated diseases.
Ukko is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ukko — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/ukko. Accessed July 19, 2026.
VCBacked. (2026). Ukko — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ukko
{{cite web |title=Ukko — Funding & Investors |url=https://www.vcbacked.co/company/ukko |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated